SAN DIEGO, CA--(Marketwired - May 28, 2014) - True Diagnostics, Inc., a company dedicated to the discovery and development of innovative diagnostic solutions, announced today that they have entered into a collaboration with Merck KGaA, Darmstadt, Germany, a world leader in providing CardioMetabolic Care. Under the agreement, True Diagnostics will collaborate with the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada to help improve and increase access to Thyroid Care in the People's Republic of China. The partnership allows the companies to provide Medical Professionals with a new and meaningful point-of-care method for rapid screening hypothyroidism patients in minutes using only a small sample of whole-blood collected directly from the patient's fingertip.
Under terms of the partnership, Merck KGaA will have the exclusive right to market and distribute in China True Diagnostics' proprietary screening assay platform and associated consumables in the Thyroid Care market. True Diagnostics, Inc. received clearance in China from the China Food and Drug Administration (CFDA) for their TrueDX™ Platform and TSH (Thyroid Stimulating Hormone) test and along with Merck KGaA look forward to improving the diagnosis rate of hypothyroidism disease aimed at helping the approximately 76 million patients in China(1) who suffer from hypothyroidism.
"We are extremely excited about our partnership with Merck in Darmstadt, Germany," said Jerry Lee, President and Chief Executive Officer of True Diagnostics. "Through our combined efforts, we will not only be the first to provide a screening option for Medical Professionals, but also provide a technology platform that will eventually help lead to improve the overall efficiency for China's Healthcare System."
(1) Weiping Teng, "Prevalence of Thyroid Disease in 10 cities in China", The 9th annual meeting of Chinese Society Endocrinology
About True Diagnostics
For the $21 billion point-of-care market, the power of the TrueDX™ Platform lies in its simplicity: tests have a 24-month shelf life; they do not require refrigeration; and laboratory quality results from small samples can now be available to clinicians in minutes. The TrueDX™Platform's simplicity, portability, and affordability also allow it to be easily adopted into emerging markets. The platform's flexible design additionally permits it to quickly commercialize a myriad of new biomarkers discoveries for cancer, autism, Alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections, and more. In essence, any biomarker utilizing traditional lab procedures, such as an ELISA or GC/MS methods can now be ported into a simple, fast, and portable assay which offers quick diagnosis and treatment at the point-of-care, point-of-incidence and remote-of-care settings. For more information, call (888) 571-8597 Ext. 702 or go to www.TrueDiagnostics.com